6-31575254-G-A

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The variant allele was found at a frequency of 0.131 in 474,386 control chromosomes in the GnomAD database, including 4,807 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).

Frequency

Genomes: 𝑓 0.14 ( 1582 hom., cov: 31)
Exomes 𝑓: 0.13 ( 3225 hom. )

Consequence

Unknown

Scores

2

Clinical Significance

drug response reviewed by expert panel U:2O:9

Conservation

PhyloP100: 0.0180

Publications

3734 publications found
Variant links:

Genome browser will be placed here

ACMG classification

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.168 is higher than 0.05.

Variant Effect in Transcripts

 

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt

Frequencies

GnomAD3 genomes
AF:
0.138
AC:
20989
AN:
152008
Hom.:
1578
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.127
Gnomad AMI
AF:
0.219
Gnomad AMR
AF:
0.0872
Gnomad ASJ
AF:
0.0839
Gnomad EAS
AF:
0.0681
Gnomad SAS
AF:
0.0691
Gnomad FIN
AF:
0.123
Gnomad MID
AF:
0.120
Gnomad NFE
AF:
0.171
Gnomad OTH
AF:
0.126
GnomAD2 exomes
AF:
0.116
AC:
17554
AN:
150892
AF XY:
0.118
show subpopulations
Gnomad AFR exome
AF:
0.119
Gnomad AMR exome
AF:
0.0594
Gnomad ASJ exome
AF:
0.0762
Gnomad EAS exome
AF:
0.0896
Gnomad FIN exome
AF:
0.120
Gnomad NFE exome
AF:
0.163
Gnomad OTH exome
AF:
0.124
GnomAD4 exome
AF:
0.128
AC:
41363
AN:
322260
Hom.:
3225
Cov.:
0
AF XY:
0.125
AC XY:
22845
AN XY:
183234
show subpopulations
African (AFR)
AF:
0.123
AC:
1151
AN:
9350
American (AMR)
AF:
0.0609
AC:
1749
AN:
28742
Ashkenazi Jewish (ASJ)
AF:
0.0803
AC:
903
AN:
11246
East Asian (EAS)
AF:
0.0760
AC:
806
AN:
10602
South Asian (SAS)
AF:
0.0760
AC:
4580
AN:
60236
European-Finnish (FIN)
AF:
0.134
AC:
1878
AN:
14012
Middle Eastern (MID)
AF:
0.170
AC:
481
AN:
2824
European-Non Finnish (NFE)
AF:
0.163
AC:
27754
AN:
169932
Other (OTH)
AF:
0.135
AC:
2061
AN:
15316
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.445
Heterozygous variant carriers
0
1608
3216
4824
6432
8040
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
146
292
438
584
730
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.138
AC:
20992
AN:
152126
Hom.:
1582
Cov.:
31
AF XY:
0.132
AC XY:
9824
AN XY:
74368
show subpopulations
African (AFR)
AF:
0.127
AC:
5287
AN:
41508
American (AMR)
AF:
0.0870
AC:
1330
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.0839
AC:
291
AN:
3470
East Asian (EAS)
AF:
0.0683
AC:
353
AN:
5168
South Asian (SAS)
AF:
0.0690
AC:
332
AN:
4814
European-Finnish (FIN)
AF:
0.123
AC:
1299
AN:
10604
Middle Eastern (MID)
AF:
0.109
AC:
32
AN:
294
European-Non Finnish (NFE)
AF:
0.171
AC:
11606
AN:
67968
Other (OTH)
AF:
0.124
AC:
262
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
921
1841
2762
3682
4603
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
232
464
696
928
1160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.156
Hom.:
6420
Bravo
AF:
0.135
Asia WGS
AF:
0.0700
AC:
243
AN:
3478

ClinVar

Significance: drug response
Submissions summary: Uncertain:2Other:9
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Susceptibility to severe coronavirus disease (COVID-19) Uncertain:1
Feb 09, 2021
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:research

Susceptibility to severe coronavirus disease (COVID-19) due to high plasma levels of TNF, TNFR, and/or TNFR4 Uncertain:1
Aug 07, 2021
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:research

Differences in plasma levels of TNFR2 according to genotypes

Malaria, cerebral, susceptibility to Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

Systemic lupus erythematosus, susceptibility to Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

Inherited susceptibility to asthma Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

etanercept response - Efficacy Other:1
Mar 24, 2021
PharmGKB
Significance:drug response
Review Status:reviewed by expert panel
Collection Method:curation

PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy

Psoriatic arthritis, susceptibility to Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

SEPTIC SHOCK, SUSCEPTIBILITY TO Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

HUMAN IMMUNODEFICIENCY VIRUS DEMENTIA, SUSCEPTIBILITY TO Other:1
Mar 01, 2006
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

Endometriosis Other:1
Oct 20, 2021
Laboratorio de Investigación del Departamento de Salud, Universidad Iberoamericana A.C.
Significance:Affects
Review Status:no assertion criteria provided
Collection Method:case-control

Mexican mestizo women with severe stage of endometriosis have higher frequencies of TNF*2-, IL1B*2- and IL1RN*2-alleles, which may explain a possible correlation with disease severity rather than predisposition or risk.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.82
CADD
Benign
2.9
DANN
Benign
0.48
PhyloP100
0.018
PromoterAI
-0.028
Neutral

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1800629; hg19: chr6-31543031; API